CMND News & Events

Polyrizon (PLRZ) entered into a development agreement with Clearmind Medicine (CMND). Under this agreement, Polyrizon will develop a proprietary intranasal formulation of MEAI, Clearmind's proprietary, next-generation, non-hallucinogenic neuroplastogen drug candidate, intended for use in the treatment of addiction-related and other central-nervous-system conditions.

Clearmind (CMND) entered into a development agreement with Polyrizon (PLRZ) Under the agreement, Clearmind has engaged Polyrizon to apply its proprietary intranasal hydrogel technology to develop an optimized formulation of Clearmind's lead proprietary compound, MEAI, a next-generation, non-hallucinogenic neuroplastogen designed for the treatment of addiction-related disorders, weight lossand other central nervous system conditions.

Clearmind Medicine welcomes the inclusion of its proprietary compound, MEAI, in newly introduced bipartisan legislation in the U.S. Congress. The Expanding Veterans' Access to Emerging Treatments Act of 2026 directs the Department of Veterans Affairs to establish an investigational research and extended access treatment program for innovative and emerging therapies that address unmet medical needs in veterans. Covered therapies explicitly include psilocybin, MDMA, MEAI, 5-MeO-DMT, ibogaine, ketamine, and others as designated by the Secretary of Veterans Affairs. This marks the first time MEAI, Clearmind's proprietary, next-generation, non-hallucinogenic neuroplastogen, has been named in U.S. federal legislation. If passed, H.R. 7091 would transform clinical treatment across a variety of covered conditions, including Alcohol Use Disorder, by developing VA-supported clinical trials and extended access protocols using these emerging treatments. "We so greatly appreciate Congress introducing H.R. 7091, which offers a transformational opportunity for veterans suffering from alcoholism, post-traumatic stress disorder and other conditions to access emerging, promising therapies. We also appreciate the recognition of MEAI, a non-hallucinogenic neuroplastogen with the transformative potential to improve the health of veterans," said CEO Adi Zuloff-Shani. "We believe, this bipartisan milestone in Washington, D.C., underscores growing support for innovative, evidence-based approaches to conditions like post-traumatic stress disorder, which remains a significant challenge for many veterans."